Important note: Information in this article was accurate in 2008. The state of the art may have changed since the publication date.
Important note: Information in this article was accurate in 2008. The state of the art may have changed since the publication date.
Reuters NewMedia - October 10, 2008
The companies also agreed to invest more in prevention, including vaccines and pre- and post-exposure prophylaxis, Ban said in a statement issued after he met with top executives at pharmaceutical and diagnostic firms working on AIDS and HIV, the virus that causes it.
"We noted that despite the gains, the epidemic continues to outstrip our best efforts. Only one-third of those who need antiretroviral treatment in low-and middle-income countries are getting it," he said.
"Each day, for every two people who are placed on antiretroviral treatment, five more are infected. Collectively, we still have more work to do."
The senior executives Ban and other U.N. officials met with were from 17 companies, including Abbott Labs, Boehringer Ingelheim, GlaxoSmithKline, Pfizer and other top industry players.
Ban said the companies agreed to "invest further in research and development of new HIV-related medicines adapted to resource-limited settings to be used safely in children, adolescents, adults and pregnant women" -- in other words, to try to make drugs available to people in poor environments.
"All participants agreed that increasing access to vaccines, diagnostics and medicines is essential in scaling up prevention and treatment efforts," Ban said.
One of the U.N. millennium development goals aimed at halving poverty by 2015 is to achieve universal access for HIV and AIDS treatment by 2010.
Some 33 million people were living with immunodeficiency virus infections in 2007, most of them in Africa, according to the latest U.N. reports on the AIDS epidemic. The disease has killed an estimated 25 million people since it was identified in the 1980s.
081010
RE081015
Copyright © 2008 - Reuters, Ltd. All rights reserved. Republication or redistribution of Reuters content is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Contact Reuters.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2008. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2008. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .